Business And Finance News, In Brief
Study Finds Personalized Medicine Increasingly Emphasized In Oncology
You may also be interested in...
TOKYO - Eisai gained its first U.S. approval for one of its in-house developed oncology products, Halaven (eribulin), but the company's blockbuster expectations may be tempered by progression-free survival data that did not meet secondary endpoints
Industry is anxiously awaiting guidance from FDA on the development of companion diagnostics for drugs that will inform efforts to move towards personalized medicine.
Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.